Iran War Impact on Medical Device Supply Chains: Strait of Hormuz, Helium Shortage, Rising Costs, and What Manufacturers Must Do

Why This Matters for Medical Device Manufacturers

The armed conflict between the United States, Israel, and Iran that began in late February 2026 is not just a geopolitical crisis. For the medical device industry, it is a supply chain disruption that is rapidly compounding across raw materials, energy, logistics, and finished goods -- and the full impact may take months to materialize, much like the COVID-19 pandemic did in 2020.

The reason is straightforward: the Strait of Hormuz, the narrow waterway between Oman and Iran through which roughly one-fifth of the world's oil passes, has been nearly completely closed since the escalation. This is not a theoretical risk. It is an active, ongoing disruption that is affecting oil, aluminum, fertilizer, sugar, and all cargo transit through one of the world's most important shipping corridors. The cascading effects reach deep into medical device manufacturing, where oil-derived plastics, helium, aluminum, and semiconductors are foundational inputs.

If you work in regulatory affairs, quality assurance, supply chain management, or manufacturing operations at a medical device company, this conflict is already your problem -- even if you do not yet feel it. The purpose of this guide is to explain exactly what is happening, which materials and device categories are most at risk, what costs are doing, and what you should be doing right now to protect your operations and your patients.

The Conflict Timeline and Shipping Disruption

Key Events

The closure of the Strait of Hormuz is the single most consequential logistics event for medical device supply chains since the Suez Canal blockage in 2021, but on a far larger scale. Unlike the Suez event, which lasted six days, the Hormuz closure is indefinite and occurs in the context of active military operations. Shipping lines face not only rerouting costs but also dramatically higher insurance premiums, crew safety concerns, and unpredictable delays.

Why the Strait of Hormuz Matters Beyond Oil

Much of the public discussion about the Strait of Hormuz focuses on oil. That focus is warranted -- oil is the single largest commodity transiting the waterway. But for medical device manufacturers, the Strait's importance extends far beyond crude:

• Aluminum: Gulf states, particularly the UAE and Bahrain, are major aluminum producers. The Strait closure has driven aluminum prices higher, affecting everything from device housings to sterile packaging.
• Helium: Qatar is one of the world's largest helium producers. Helium from Qatar transits the region by ship and pipeline. The Iranian attack on Qatar's helium production infrastructure on March 18, 2026, has removed a massive chunk of global supply.
• General cargo and container shipping: Even goods not produced in the Gulf region pass through or near the Strait on Asia-to-Europe and Asia-to-Americas routes. Diversion around the Cape of Good Hope adds 10 to 14 days and substantial cost.
• Pharmaceutical transit: The Gulf Cooperation Council (GCC) transit hubs -- Dubai, Doha, and others -- serve as primary corridors for pharmaceutical trade between manufacturing centers in South Asia and markets in Europe, Africa, and the Middle East. Disruption at these hubs directly affects drug availability.

Critical Materials at Risk

Helium: The MRI and Semiconductor Crisis

The most acute and immediate supply chain risk for the medical device industry is helium. The March 18, 2026, Iranian attack on Qatar's major helium production site has removed approximately one-third of global helium supply from the market virtually overnight.

Why helium matters for medical devices:

• MRI machines: Helium is essential for cooling superconducting magnets in MRI systems. The global installed base of MRI machines supports more than 95 million scans per year. MRI magnets require periodic helium replenishment. Without it, magnets quench -- a costly and potentially damaging event that takes machines offline for extended periods.
• Semiconductor manufacturing: Helium is used in semiconductor fabrication processes, including as a carrier gas in chemical vapor deposition and as a cooling medium. Medical devices increasingly rely on advanced semiconductors for imaging, diagnostics, patient monitoring, and therapeutic functions. A helium shortage that constrains semiconductor production creates a second-order supply crisis for medical device manufacturers.
• Leak testing: Helium is the standard tracer gas for leak testing in medical device manufacturing, used extensively for verifying hermetic seals in implantable devices, drug delivery systems, and sterile barrier systems.

What is happening in the market:

Air Liquide, one of the world's largest industrial gas companies and a major helium supplier, is actively assessing customer stockpiles and diversifying helium sources. This language, from industry reporting, signals that the situation is serious enough that the largest players in the space are in crisis management mode. When a company like Air Liquide is assessing stockpiles, it means the market is already tight enough that allocation is under discussion.

Practical implications:

Oil-Derived Plastics: The Foundation of Device Manufacturing

Oil price surges triggered by the Strait of Hormuz closure have a direct and material impact on medical device manufacturing because an enormous proportion of medical devices and their packaging are derived from petroleum. As one industry source quoted by AAMI put it: "If that supply is pinched, you can't get crude supplies to plants that make ethylene and polyethylene, that means prices go up."

This is not an abstract economic statement. It describes the literal chain of causation:

1. Crude oil supply is constrained by the Strait of Hormuz closure.
2. Petrochemical plants that crack crude into ethylene, propylene, and other base chemicals receive less feedstock or pay more for it.
3. Polymer plants that convert ethylene and propylene into polyethylene, polypropylene, PVC, and other medical-grade resins face higher input costs.
4. Device manufacturers and contract manufacturers that purchase these resins for molding, extrusion, and film production see rising costs and potential allocation.

Device categories most exposed to oil-based plastic disruption:

• IV bags (PVC, polyolefin films)
• Syringes (polypropylene barrels and plungers)
• Catheters (nylon, polyurethane, PEBAX)
• Diagnostic device casings (ABS, polycarbonate, polypropylene)
• Sterile barrier systems and packaging (Tyvek, polyethylene films)
• Personal protective equipment (polypropylene nonwovens, nitrile)

The critical point is that these are not specialty materials used in small volumes. They are the bulk materials of medical device manufacturing. A sustained increase in resin prices flows through to virtually every device category.

Aluminum

Aluminum prices have risen due to the Strait of Hormuz closure, as GCC producers are significant global suppliers. For medical device manufacturers, aluminum is used in:

• Device housings and enclosures for imaging equipment, patient monitors, and surgical instruments
• Cans and containers for sterilization
• Heat sinks for electronic medical devices
• Packaging components

While aluminum is not as universally critical as oil-derived plastics across all device categories, the price increase compounds the overall cost pressure on manufacturers already dealing with higher energy and freight costs.

Semiconductors

The semiconductor situation for medical devices is a double hit:

1. Helium shortage constrains semiconductor fabrication, as described above. Helium is used in multiple steps of chip manufacturing, and a sustained shortage could reduce output at a time when semiconductor demand continues to grow across all sectors.
2. Freight disruption affects semiconductor supply chains, which are globally distributed -- design in one country, fabrication in another, packaging and testing in a third, integration into finished devices in a fourth. Each link in this chain is vulnerable to shipping delays and cost increases.

Medical devices are particularly exposed to semiconductor supply constraints because the industry is a relatively low-volume buyer compared to consumer electronics and automotive. When supply tightens, medical device manufacturers are not the priority customers for semiconductor foundries. This dynamic played out during the 2021-2023 semiconductor shortage, and the same pattern is likely to recur.

Impact on Specific Device Categories

Not all medical devices are equally exposed to the Iran war supply chain disruption. The following table summarizes the risk level and primary drivers for major device categories:

Rising Costs and Freight Disruption

The Cost Cascade

The Iran war is driving cost increases at every level of the medical device supply chain. These are not marginal increases:

• Raw material costs: Oil-derived resins, aluminum, and helium are all experiencing significant price increases driven by supply constraints rather than demand shifts.
• Freight costs: Shipping companies are imposing "conflict surcharges" on top of already elevated base rates. Some shipping lines have diverted vessels away from the Gulf entirely, routing around the Cape of Good Hope, which adds 10 to 14 days of transit time and correspondingly higher fuel and crew costs. Other lines have temporarily halted services to certain Gulf ports altogether.
• Insurance premiums: Marine cargo insurance premiums for shipments transiting or near the Gulf region have increased dramatically. War risk premiums, which had been relatively stable in recent years, have spiked.
• Drug costs: In certain regions, pharmaceutical costs have quadrupled due to transportation delays and soaring insurance premiums. This is most acute in markets that depend on the GCC transit hubs for pharmaceutical imports.

Why This Hits Medical Devices Especially Hard

Medical device manufacturing operates on cost structures that make these increases particularly painful:

• Single-use devices (syringes, IV sets, catheters, PPE) are high-volume, low-margin products where raw material costs represent a large proportion of total cost. A 20 to 30 percent increase in resin prices can eliminate margins entirely.
• Regulatory constraints prevent rapid supplier switching. Unlike consumer goods companies, medical device manufacturers cannot simply switch to a cheaper resin or an alternative supplier. Material changes may require design verification testing, biocompatibility retesting per ISO 10993, process revalidation, and potentially a new 510(k) submission or Notified Body notification. The timeline and cost of these changes can be enormous.
• Contract pricing delays the pass-through. Many medical device sales are made through group purchasing organizations (GPOs), integrated delivery networks (IDNs), or government tenders with fixed pricing over multi-year terms. Manufacturers cannot easily pass cost increases through to customers, which means they absorb the margin compression.
• Quality system requirements. Under both the FDA's QMSR (which now incorporates ISO 13485) and the EU MDR, manufacturers must maintain validated processes and qualified suppliers. Disruption to supply chains does not relieve regulatory obligations. If a supplier change is forced by circumstances, the regulatory burden of qualifying the new supplier remains.

Cold Chain and Pharmaceutical Transit

The disruption at GCC transit hubs -- Dubai, Doha, and the broader Gulf logistics infrastructure -- is particularly concerning for cold-chain products, which include temperature-sensitive pharmaceuticals and biologics that are often co-manufactured or co-packaged with medical devices (combination products, prefilled syringes, drug-device combinations).

Products at risk:

• Vaccines: Many vaccines require strict cold-chain maintenance (2 to 8 degrees Celsius for most, ultra-cold for some). Transit delays at GCC hubs, where temperature-controlled storage may be overwhelmed or inaccessible, threaten product integrity.
• Insulin and specialty biologics: These products have narrow temperature tolerance windows and fixed shelf lives. Extended transit times can render them ineffective or unsafe.
• Diagnostic reagents and test kits: Many in vitro diagnostic reagents require refrigerated storage and transport. Delays compromise analytical performance and may necessitate disposal and reshipment.

The pharmaceutical dimension matters for medical device companies because:

1. Combination products (drug-device combinations) are subject to both drug and device supply chain constraints simultaneously.
2. IVD manufacturers depend on reagent supply chains that overlap with pharmaceutical logistics networks.
3. Hospitals and healthcare systems facing pharmaceutical shortages may defer procedures that require medical devices, creating indirect demand suppression.

Drug costs quadrupling in certain regions, as reported in current analyses, is a leading indicator of what may happen in medical device markets if the disruption persists. The same logistics bottlenecks and insurance premiums driving pharmaceutical cost inflation apply to medical device distribution.

What Medical Device Manufacturers Should Do Now

Based on expert recommendations from industry analysts, trade associations, and supply chain specialists, the following actions are advisable for medical device manufacturers of all sizes.

Immediate Actions (0-30 Days)

1. Map your supply chain exposure. Identify every critical material, component, and supplier that has a direct or indirect dependency on Gulf region logistics, oil-derived inputs, helium, or aluminum. This mapping should go beyond Tier 1 suppliers to include Tier 2 and Tier 3 suppliers where possible. Many device manufacturers discovered during COVID-19 that they did not know who their Tier 2 and Tier 3 suppliers were until those suppliers failed.

2. Assess helium dependency. If your products or manufacturing processes use helium -- for MRI magnet service, leak testing, semiconductor procurement, or analytical instruments -- determine your current inventory, your suppliers' inventory, and your expected consumption rate. Contact your helium supplier immediately to understand allocation status and lead times.

3. Review resin and polymer contracts. If you purchase medical-grade resins (polyethylene, polypropylene, PVC, polyurethane, PEBAX, polycarbonate, or others), review your contracts for force majeure clauses, price escalation provisions, and allocation terms. Understand your contractual position if your supplier invokes force majeure or imposes allocation.

4. Evaluate safety stock levels. For critical materials and components at risk, assess whether your current safety stock levels are adequate for a prolonged disruption. The standard industry practice of maintaining 4 to 8 weeks of safety stock may be insufficient for a disruption that could last months.

5. Activate your supply chain risk management plan. If you have a documented supply chain risk management process (as required by ISO 13485 Clause 7.4 and recommended by FDA guidance), activate it. If you do not have one, this crisis is your wake-up call to build one. See our Medical Device Supply Chain Risk Management Guide for a comprehensive framework.

Short-Term Actions (1-3 Months)

6. Qualify alternative suppliers. Begin the process of qualifying backup suppliers for your most critical and exposed materials. This is not a quick process in medical devices -- it requires supplier evaluation, incoming inspection qualification, process validation, biocompatibility assessment where applicable, and potentially regulatory submissions. Starting now is essential because the qualification timeline can run 6 to 18 months.

7. Pursue dual-sourcing for single-source dependencies. If you have any critical material or component supplied by a single source -- particularly one with exposure to Gulf region logistics -- treat this as an urgent risk. Dual-sourcing does not mean splitting volume equally; even having a qualified but inactive secondary supplier provides a critical option during disruption.

8. Engage with customers and GPOs. If you anticipate cost increases or supply constraints that will affect your ability to deliver, communicate early with your customers, GPO contract managers, and distribution partners. Early communication is always preferable to late surprises. Where possible, negotiate cost-sharing mechanisms or pricing adjustment provisions.

9. Assess regulatory implications of any supply changes. Before implementing any material or supplier change, evaluate the regulatory impact. Under the QMSR and ISO 13485, changes to critical suppliers or materials require documented risk assessment, verification, and potentially regulatory notification. Work with your regulatory affairs team to classify each planned change and determine the appropriate regulatory pathway.

Strategic Actions (3-12 Months)

10. Evaluate reshoring and nearshoring options. The Iran war is accelerating an existing trend toward healthcare reshoring -- bringing manufacturing closer to end markets to reduce exposure to geopolitical disruption. This is a strategic decision with significant capital investment implications, but the current crisis is strengthening the business case. For more on this trend, see our discussion below.

11. Shorten and simplify your supply chains. Every link in your supply chain that depends on international shipping through a chokepoint like the Strait of Hormuz, the Suez Canal, or the Strait of Malacca is a vulnerability. Evaluate opportunities to reduce the number of logistics links between raw material and finished device.

12. Invest in supply chain visibility technology. The medical device industry lags behind automotive and consumer electronics in supply chain digitization. Real-time visibility into supplier inventory, logistics status, and risk exposure is no longer a nice-to-have. It is a competitive necessity.

Lessons from COVID-19 Supply Chain Disruption

The medical device industry has been through a major supply chain disruption before. The COVID-19 pandemic, beginning in early 2020, exposed critical vulnerabilities in medical device supply chains -- single-source dependencies, inadequate safety stock, limited supply chain visibility, and an inability to qualify alternative suppliers quickly enough.

The parallels to the current situation are instructive and concerning:

Key lesson: the full impact takes months to materialize. Multiple expert sources have noted that, like COVID-19, the Iran war's impact on medical device supply chains could take months to fully materialize. This is because:

• Existing inventory buffers mask the initial disruption. Many manufacturers carry 4 to 12 weeks of raw material and component inventory. The supply chain disruption does not become visible on the production line until those buffers are consumed.
• Contract manufacturers and Tier 2/3 suppliers may absorb short-term cost increases before passing them through, delaying the price signal.
• Qualification and regulatory timelines for alternative suppliers mean that even companies that respond quickly will not see the benefits for months.
• Semiconductor supply effects are particularly lagged because of the long fabrication cycle (wafer fabrication takes 8 to 12 weeks before assembly and testing).

The companies that navigated COVID-19 best were those that responded early, communicated transparently, and had already invested in supply chain diversification before the crisis hit. The same will be true here.

The Reshoring and Diversification Trend

The Iran war is not creating a new trend in healthcare supply chain strategy. It is accelerating one that was already underway, driven by COVID-19 experience, US-China trade tensions, tariff escalation, and a growing recognition that lean, globally distributed supply chains optimized purely for cost are fragile.

The reshoring argument for medical devices:

• Proximity to regulated markets. Manufacturing in or near your primary regulatory markets (US, EU) reduces exposure to international shipping disruptions and simplifies regulatory oversight.
• Shorter supply chains are more resilient. Every transoceanic shipping link is a potential point of failure. Manufacturing closer to end markets eliminates chokepoint dependencies like the Strait of Hormuz, the Suez Canal, and the Strait of Malacca.
• Government incentives are growing. Multiple governments, including the United States, are offering incentives for domestic manufacturing of critical healthcare products. The current crisis is likely to increase political pressure for further incentives.
• Dual-sourcing is the minimum standard. Industry experts consistently recommend dual-sourcing as a baseline risk mitigation strategy. Companies that relied on single-source suppliers -- particularly those with geographic concentration in vulnerable regions -- are the ones most exposed today.

The case for diversification over consolidation:

For decades, the trend in medical device manufacturing was toward consolidation -- fewer, larger, more specialized suppliers in lower-cost geographies. That strategy optimized for cost but created concentration risk. The Iran war, following COVID-19, following the Suez Canal blockage, is the third major disruption in six years to demonstrate that concentration risk in medical device supply chains is unacceptable.

The emerging best practice is diversified, regionalized supply chains -- multiple qualified suppliers distributed across geographies, with manufacturing capacity located in or near major end markets. This is more expensive in steady state but dramatically more resilient during disruption.

Key Variables to Watch

The trajectory of the medical device supply chain impact from the Iran war depends on several variables that are impossible to predict with certainty but essential to monitor:

1. Duration of the Strait of Hormuz closure. The single most important variable. A closure lasting weeks will cause price spikes and temporary shortages. A closure lasting months will cause structural supply chain reconfiguration. A closure lasting a year or more will fundamentally reshape where and how medical devices are manufactured.

2. Whether additional attacks on Gulf infrastructure occur. The March 18 attack on Qatar's helium production site demonstrated the conflict's potential to expand beyond Iranian territory. Further attacks on GCC infrastructure -- ports, petrochemical plants, desalination facilities -- would compound the disruption.

3. The helium supply response. Can helium production in the United States, Russia, and other non-Qatari sources increase sufficiently to offset the loss of Qatari supply? Air Liquide and other major suppliers are working on this, but helium is not a commodity that can be ramped quickly. New helium production capacity takes years to develop.

4. Oil price trajectory. Oil prices affect every downstream petrochemical input. If prices stabilize at elevated levels, the cost impact is manageable but persistent. If prices continue to rise, the cost pressure on oil-derived medical device materials becomes severe.

5. Semiconductor supply chain resilience. The medical device industry competes with consumer electronics, automotive, and defense for semiconductor capacity. A helium-driven semiconductor production cut will trigger allocation decisions by foundries. Medical device manufacturers need to understand where they stand in their foundry partners' priority hierarchy.

6. Government and regulatory response. Will the FDA, EMA, or other regulators issue guidance or enforcement discretion policies related to supply chain disruption, similar to what was seen during COVID-19? Will governments invoke strategic stockpile releases for critical medical materials? Will export restrictions be imposed on critical materials? These policy decisions can significantly alter the market dynamics.

7. Clinical trial disruption in the Gulf. Clinical trials in the Gulf region are disrupted by the conflict. For sponsors running trials in Saudi Arabia, the UAE, Qatar, or other GCC states, site activation, patient enrollment, investigational product supply, and monitoring visits are all affected. Sponsors should assess the impact on their clinical development timelines and consider alternative sites.

Final Assessment

The Iran war's impact on medical device supply chains is real, it is growing, and it will get worse before it gets better. The Strait of Hormuz closure and the attack on Qatar's helium production have created material supply constraints in helium, oil-derived plastics, aluminum, and semiconductors -- all foundational inputs for medical device manufacturing. Freight costs are rising through conflict surcharges and insurance premiums. Drug costs have quadrupled in some regions. The full impact will take months to materialize as inventory buffers are consumed and contract terms play out.

Medical device manufacturers that learned the lessons of COVID-19 -- the importance of supply chain visibility, dual-sourcing, safety stock, and proactive communication -- will navigate this crisis more effectively than those that did not. For companies that treated supply chain as a procurement problem rather than a strategic and regulatory function, this is a second and perhaps final wake-up call.

The recommended actions in this guide are not theoretical. They are practical steps that regulatory affairs, quality assurance, supply chain, and manufacturing professionals can take today to reduce risk, protect their operations, and ultimately protect the patients who depend on the devices they produce.